Data Year:

For its 2023 fiscal year, DBV TECHNOLOGIES S A, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2023
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Pharis Mohideen
Chief Medical Officer
Total Compensation $1,279,518 View details Pay Rank By Title In Biotechnology industry #283 View more
Daniel Tassé
Chief Executive Officer and Director
Total Compensation $2,404,486 View details Pay Rank By Title In Biotechnology industry #455 View more
Sébastien Robitaille
Former Chief Financial Officer
Total Compensation $379,286 View details Pay Rank By Title In Biotechnology industry #619 View more
Virginie Boucinha
Chief Financial Officer
Total Compensation $234,626 View details Pay Rank By Title In Biotechnology industry #691 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at DBV TECHNOLOGIES S A as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. DBV TECHNOLOGIES S A income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. DBV TECHNOLOGIES S A annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Pharis Mohideen
Chief Medical Officer
Total Cash $763,106 Equity $350,119 Other $166,293 $1,279,518
Daniel Tassé
Chief Executive Officer and Director
Total Cash $1,200,000 Equity $1,084,783 Other $119,703 $2,404,486
Sébastien Robitaille
Former Chief Financial Officer
Total Cash $344,286 Equity $35,000 Other $0 $379,286
Virginie Boucinha
Chief Financial Officer
Total Cash $49,538 Equity $185,088 Other $0 $234,626
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.